Skip to main content
Premium Trial:

Request an Annual Quote

Inivata, N-of-One Partner to Provide Interpretation, Clinical Trial Matching for Cancer Patients

NEW YORK (GenomeWeb) –N-of-One has agreed to provide Inivata with analysis support for its InVision liquid biopsy product line.

Under the terms of the agreement, N-of-One will provide oncologists with individualized reports for patients tested with Inivata's ctDNA-based 34 gene panel. The InVision panel uses a tagged-amplicon sequencing method prior to sequencing, which enables amplification and deep sequencing of genomic regions spanning thousands of bases from individual copies of fragmented DNA.

Last month, Inivata launched its first prospective clinical validation study in non-small cell lung cancer (NSCLC). The study, which will be completed in July 2017, is expected to recruit several hundred patients across more than 30 center in the US. It is intended to evaluate the performance of Inivata's liquid biopsy platform compared to tissue-based molecular profiling in patients with advanced NSCLC.

N-of-One's reports will cover suggested treatment strategies and clinical trial opportunities that are tailored to each patients' unique genomic signature. The company's "experience in curating complex genomic information and translating this data into clinically relevant results on tens of thousands of patients has enabled them to develop a market-leading database and unparalleled expertise," Inivata CEO Michael Stocum said in a statement. "We are excited to access their capabilities to ensure we provide physicians with the most actionable information."

The partnership "has the potential to help guide more personalized treatment decisions for patients prior to and throughout the cancer care continuum," N-of-One CEO Chris Cournoyer added.